Comparison of Body Weight Change During Contraception With Belara and Yasmin

• Status: Unknown status
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate different side effect in contraceptive use of two oral combined contraceptive pills (OCP)in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®) and 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®), especially body weight change.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mahidol University
• Treatments: Chlormadinone Acetate; Drospirenone; Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol

Criteria

Inclusion Criteria:

• Reproductive woman

• Woman who has BMI < 28.5 kg/m2.

• Woman who has regular menstruation.

• Woman who don't have pelvic organ disorder.

• Woman who want contraception with oral contraceptive pills.

Exclusion Criteria:

• Woman who has abnormal blood pressure

• Woman who has abnormal vaginal bleeding

• Pregnant woman

• Woman who on medication effect contraceptive pills, such as anti-fungal, anti-retroviral, anti-convulsant drug.

• Woman who has contraindication for OCP.

• Woman who use steroid in 3 month period before enrollment in this study.

• Smoking

• Woman who has eating habit disorder.